Literature DB >> 32167940

Glycogen-rich Clear Cell Carcinoma of the Breast: A Comprehensive Review.

Semir Vranic1, Faruk Skenderi2, Vanesa Beslagic3, Zoran Gatalica4.   

Abstract

Glycogen-rich clear cell carcinoma (GRCC) is a very rare form of primary breast cancer (<0.1% of all breast cancers). It is characterized by the presence of neoplastic cells with a glycogen-abundant clear cytoplasm (the Periodic Acid Schiff-positive, diastase-sensitive). The expression of steroid receptors (estrogen and progesterone receptors) has been variably reported (35% to 100% of the cases), whereas most studies reported low human epidermal growth factor receptor 2 positivity in GRCC. High androgen receptor positivity without androgen receptor splice variant-7 was reported in one recent study. Although sparse, the preliminary theranostic data on GRCC indicate the potential of targeted treatments in selected cases (antiandrogen, PIK3CA, and immune checkpoint inhibitors). Because of its rarity, the prognosis for GRCC patients remains controversial. Herein, we comprehensively appraise the epidemiological, morphologic, molecular, and clinical characteristics of this rare mammary malignancy.

Entities:  

Year:  2020        PMID: 32167940     DOI: 10.1097/PAI.0000000000000850

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  4 in total

1.  Novel targetable biomarkers in clear cell carcinoma of the breast uncovered by molecular profiling: A study of nine cases.

Authors:  Faruk Skenderi; Juan Palazzo; Jeffrey Swensen; Rebecca Feldman; Elma Contreras; Elena Florento; Zoran Gatalica; Semir Vranic
Journal:  Breast J       Date:  2020-04-11       Impact factor: 2.431

2.  Glycogen-rich clear cell carcinoma of the breast with solid papillary pattern: Two cases with heterogeneous clinicopathological features.

Authors:  Tiberiu-Augustin Georgescu; Octavian Munteanu; Antonia-Carmen Lisievici; Tiberiu Tebeică; Dragoș Crețoiu; Oana Toader; Nicolae Suciu; Roxana Elena Bohîlțea
Journal:  Exp Ther Med       Date:  2021-03-22       Impact factor: 2.447

3.  MYCT1 alters the glycogen shunt by regulating selective translation of RACK1-mediated enzymes.

Authors:  Dong-Xue Ding; Yue Wang; Wei Yan; Wei-Neng Fu
Journal:  iScience       Date:  2022-02-22

4.  Clinicopathologic and Genomic Features in Triple-Negative Breast Cancer Between Special and No-Special Morphologic Pattern.

Authors:  Ying-Zi Li; Bo Chen; Xiao-Yi Lin; Guo-Chun Zhang; Jian-Guo Lai; Cheukfai Li; Jia-Li Lin; Li-Ping Guo; Wei-Kai Xiao; Hsiaopei Mok; Chong-Yang Ren; Ling-Zhu Wen; Fang-Rong Cao; Xin Lin; Xiao-Fang Qi; Yang Liu; Ning Liao
Journal:  Front Oncol       Date:  2022-03-25       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.